Pfizer halts enrolment in Phase III lung cancer trial of novel anticancer
13 October 2009
Malini Guha
Please Login to read the full article.
13 October 2009
Malini Guha
Pfizer has halted new patient enrolment in a pivotal Phase III trial of its novel insulin-like growth factor 1 (IGF-1) receptor antagonist, figitumumab (CP-751,871), testing it as a first-line treatment in non-adenocarcinoma non-small cell lung cancer (NSCLC), after the trial's independent...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Astellas mulls darexaban alliances as pipeline moves forward
- Amgen/Takeda's $0-rated motesanib fails Phase III lung cancer trial
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- GSK expands tiered pricing approach in India with Votrient and Revolade launches
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
